Novo Nordisk’s Forma Buy Builds On Foothold In Rare Blood Disorders
Executive Summary
Novo's head of rare disease Ludovic Helfgott talked to Scrip about the $1.1bn acquisition and expansion into sickle cell disease.
You may also be interested in...
Rigel Ready To Hit The Ground Running After Early AML Drug Approval
Rezlidhia, which was only recently licensed by Rigal from Novo Nordisk-owned Forma Therapeutics, should challenge the market dominance of Servier's Tibsovo in the IDH-1 inhibitor subset of acute myeloid leukemia patients.
Deals In Depth: September 2022
Just one $1bn+ alliance was penned in September compared to eight that were signed in August.
Novo Nordisk Committed To Advancing In Cardiovascular
The Danish major’s head of development tells Scrip that as cardiovascular disease is very closely related to obesity and diabetes, Novo Nordisk has the expertise to thrive in the former.